


# ACS Fall 2023: First Disclosures

## TNG-462


oral MTA-cooperative PRMT5 inhibitor



TANGO THERAPEUTICS, BOSTON, MA

## STC15


oral METTL3 inhibitor



STORM THERAPEUTICS, CAMBRIDGE, UK

## STX-478


oral PI3K $\alpha$  allosteric inhibitor



SCORPION THERAPEUTICS, BOSTON, MA

## JNT-517


oral SLC6A19 allosteric inhibitor



JNANA THERAPEUTICS, BOSTON, MA

## CHK-336


oral LDHA inhibitor



CHINOOK THERAPEUTICS, VANCOUVER, CA

## GDC-6599


TRPA1 inhibitor



GENENTECH, SOUTH SAN FRANCISCO, CA

## KIN-3248


oral pan-FGFR inhibitor



KINNATE BIOPHARMA, SAN DIEGO, CA

## NX-5948


oral BTK protein degrader



NURIX THERAPEUTICS, SAN FRANCISCO, CA

## KT-474


oral IRAK-4 degrader



KYMERA, WATERTOWN, MA

## RPT193


oral CCR4 inhibitor



RAPT THERAPEUTICS, SO. SAN FRANCISCO, CA

## EDIO48


oral CpPI(4)K inhibitor



NOVARTIS, BASEL, CH

## PF-07817883

oral SARS-CoV-2 M<sup>pro</sup> inhibitor



PFIZER, CAMBRIDGE, MA / GROTON, CT